Download Files:
Products Details
Product Description
– Ulecaciclib is an orally activitive inhibitor of cyclin-dependent kinase (CDK), with Ki values of 0.62 μM (CDK2/Cyclin A), 0.2 nM (CDK4/Cyclin D1), 3 nM (CDK6/Cyclin D3), and 0.63 μM (CDK7/Cyclin H), respectively. Ulecaciclib can cross blood brain barrier and has good pharmacokinetic characteristics[1][2][3].
Web ID
– HY-147409
Shipping
– Room temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C25H33FN8S
References
– [1]International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information. 2022. 36(2):337.|[2]Wang Shudong, et al. Treatment of proliferative diseases of the CNS using a class of thiazole-pyrimidine compounds that inhibit the activity of CDK4 and/or CDK6[P]. World Intellectual Property Organization, WO2021222967 A1 2021-11-11.|[3]Wang Shudong, et al. Succinate and crystal form thereof as therapeutics[P]. World Intellectual Property Organization, WO2022099357 A1 2022-05-19.
CAS Number
– 2075750-05-7
Molecular Weight
– 496.65
SMILES
– FC1=C(C2=C(C)N=C(NC3CCCC3)S2)N=C(NC4=NC=C(CN5CCN(CC5)CC)C=C4)N=C1
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– CDK
Isoform
– CDK2;CDK4;CDK6;CDK7
Pathway
– Cell Cycle/DNA Damage
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
